SFM
OTLK icon

Sphera Funds Management’s Outlook Therapeutics OTLK Stock Holding History

Sphera Funds Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-857,142
Closed -$1.05M – 126
2025
Q1 		$1.05M Buy
+857,142
New +$1.5M 0.24% 89
2024
Q4 		– Sell
-413,545
Closed -$2.21M – 123
2024
Q3 		$2.21M Sell
413,545
-157,883
-28% -$1.16M 0.35% 79
2024
Q2 		$4.22M Sell
571,428
-1
-0% -$8 0.58% 56
2024
Q1 		$6.82M Buy
+571,429
New +$4.62M 0.96% 37
2017
Q1 		– Sell
-1,090
Closed -$525K – 121
2016
Q4 		$525K Sell
1,090
-160
-13% -$89.6K 0.13% 91
2016
Q3 		$850K Sell
1,250
-369
-23% -$235K 0.14% 96
2016
Q2 		$881K Buy
+1,619
New +$966K 0.23% 80

Other funds holding OTLK

SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Sphera Funds Management's OTLK Position: Q2 2025 in Review

Sphera Funds Management sold out of Outlook Therapeutics (OTLK) in Q2 2025, closing a stake of 857,142 shares — an estimated $1.05M sold.

Sphera Funds Management first reported a position in OTLK in Q2 2016 and held it in 7 quarters. The position peaked at $6.82M in Q1 2024. 66 funds tracked by Wall St. Rank hold OTLK as of Q2 2025.

  • Sphera Funds Management reported no remaining Outlook Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Sphera Funds Management sold 857,142 Outlook Therapeutics shares in Q2 2025, an estimated $1.05M.
  • Sphera Funds Management first reported a position in Outlook Therapeutics in Q2 2016 and held it in 7 quarters.
  • Sphera Funds Management's Outlook Therapeutics position peaked at $6.82M in Q1 2024.
  • 66 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2025.

Based on Sphera Funds Management's 13F filing for Q2 2025, filed 14 Aug 2025.